NovaBay Pharmaceuticals (NYSE:NBY) Now Covered by StockNews.com

StockNews.com began coverage on shares of NovaBay Pharmaceuticals (NYSE:NBY) in a research report released on Sunday. The brokerage issued a hold rating on the stock.

Separately, Ascendiant Capital Markets dropped their price objective on shares of NovaBay Pharmaceuticals from $8.00 to $0.85 and set a “buy” rating on the stock in a report on Monday, November 11th.

NovaBay Pharmaceuticals Price Performance

NBY stock opened at $0.70 on Friday. The stock has a market capitalization of $3.42 million, a price-to-earnings ratio of -0.01 and a beta of 0.65. The company has a 50-day moving average of $0.62 and a two-hundred day moving average of $0.83. NovaBay Pharmaceuticals has a 52-week low of $0.36 and a 52-week high of $9.08.

NovaBay Pharmaceuticals Company Profile

NovaBay Pharmaceuticals, Inc, a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands.